Clinical Trials Logo

Clinical Trial Summary

The VITALYST Early Feasibility study (EFS) is designed to evaluate the feasibility and safety of the VITALYST System in subjects undergoing elective high-risk percutaneous coronary intervention (HR-PCI).


Clinical Trial Description

The VITALYST EFS is a prospective, open-label, single-arm, multicenter feasibility study of the VITALYST System. The VITALYST System will be used to provide temporary circulatory support in patients undergoing non-emergent high risk percutaneous interventions (HR-PCI). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06132568
Study type Interventional
Source Boston Scientific Corporation
Contact Alison Osattin
Phone 800-876-9960
Email alison.osattin@bsci.com
Status Recruiting
Phase N/A
Start date May 9, 2024
Completion date December 2024

See also
  Status Clinical Trial Phase
Active, not recruiting NCT04477603 - Impella ECP Early Feasibility Study N/A
Recruiting NCT05727059 - Magenta Elevateā„¢ EFS in High-Risk PCI Patients N/A
Recruiting NCT04321148 - Protect Kidney Trial N/A
Enrolling by invitation NCT05334784 - Impella ECP Study (ECP Study) and Impella ECP Continued Access Protocol N/A
Active, not recruiting NCT06099548 - Magenta Elevateā„¢ First-in-Human Clinical Study in High-Risk PCI Patients N/A